Disclosed are compositions and methods related to the use of adipocytes for sustained release of anti-cancer therapeutics and treatment of cancer. In one aspect, disclosed herein are engineered adipocytes comprising an anti-cancer prodrug (such as, for example, doxorubicin prodrug) and a conjugated fatty acid (such as, for example, one or more isomers of conjugated linoleic acid including, but not limited, to 9cis, 11trans, 10trans, and/or 12cis).L'invention concerne des compositions et des méthodes se rapportant à l'utilisation d'adipocytes pour la libération prolongée d'agents thérapeutiques anticancéreux et le traitement du cancer.
